Trials / Completed
CompletedNCT01879618
Use Of Fragmin In Hemodialysis
A Phase IIIb Open Label Study To Optimize The Single Bolus Dose Of Dalteparin Sodium For The Prevention Of Clotting Within The Extracorporeal System During Hemodialysis Procedures For Subjects With Chronic Renal Insufficiency: The Parrot Study
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 152 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The study will determine if the Fragmin dose can be adjusted to suit the clinical needs of patients during dialysis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fragmin | variable dosing regimen |
Timeline
- Start date
- 2013-10-01
- Primary completion
- 2016-03-01
- Completion
- 2016-03-01
- First posted
- 2013-06-18
- Last updated
- 2017-03-10
- Results posted
- 2016-12-29
Locations
19 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT01879618. Inclusion in this directory is not an endorsement.